Overview

  • Product name

    Anti-Tet2 antibody - N-terminal
    See all Tet2 primary antibodies
  • Description

    Rabbit polyclonal to Tet2 - N-terminal
  • Host species

    Rabbit
  • Tested applications

    Suitable for: IHC-P, WB, IP, ICC/IF, ChIPmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human Tet2 (N terminal). The exact sequence is proprietary.
    Database link: Q6N021

  • Positive control

    • ICC/IF: HeLa cells. IP: HEK-293T whole cell extract. WB: HEK-293T, A431, HeLa and HepG2 whole cell lysate (ab7900); DDDDK-human Tet2-transfected HEK-293T whole cell lysate. ChIP: U-2 OS chromatin extract. IHC-P: Human breast cancer and cervical carcinoma tissues.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer

    pH: 7.00
    Preservative: 0.01% Thimerosal (merthiolate)
    Constituents: PBS, 20% Glycerol
  • Concentration information loading...
  • Purity

    Immunogen affinity purified
  • Clonality

    Polyclonal
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab230358 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/100 - 1/1000.
WB 1/500 - 1/10000. Predicted molecular weight: 224 kDa.
IP 1/100 - 1/500.
ICC/IF 1/100 - 1/1000.
ChIP Use at an assay dependent concentration.

Target

  • Function

    Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation.
  • Tissue specificity

    Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes.
  • Involvement in disease

    Note=TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites.
    Defects in TET2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
    Note=TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen.
    Note=TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites.
  • Sequence similarities

    Belongs to the TET family.
  • Information by UniProt
  • Database links

  • Alternative names

    • FLJ20032 antibody
    • KIAA1546 antibody
    • MDS antibody
    • Methylcytosine dioxygenase TET2 antibody
    • Nbla00191 antibody
    • Probable methylcytosine dioxygenase TET2 antibody
    • Protein Ayu17 449 antibody
    • Tet 2 antibody
    • Tet methylcytosine dioxygenase 2 antibody
    • Tet oncogene 2 antibody
    • Tet oncogene family member 2 antibody
    • TET2 antibody
    • TET2_HUMAN antibody
    see all

Images

  • All lanes : Anti-Tet2 antibody - N-terminal (ab230358) at 1/500 dilution

    Lane 1 : HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate/extract
    Lane 2 : A431 (Human epidermoid carcinoma cell line) whole cell lysate/extract
    Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate/extract
    Lane 4 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate/extract

    Lysates/proteins at 30 µg per lane.

    Secondary
    All lanes : HRP-conjugated anti-rabbit IgG

    Predicted band size: 224 kDa



    5% SDS-PAGE gel.

  • 4% paraformaldehyde-fixed HeLa (human epithelial cell line from cervix adenocarcinoma) cells stained for Tet2 (green) using ab230358 at 1/1000 dilution in ICC/IF.

    Counterstain: Hoechst 33342 (blue), alpha tubulin (red).

  • Tet2 was immunoprecipitated from HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell extract with 5 µg ab230358. Western blot was performed from the immunoprecipitate using ab230358. Anti rabbit IgG antibody was used as secondary antibody.

    Lane 1: Control IgG IP in HEK-293T whole cell lysate.

    Lane 2: ab230358 IP in HEK-293T whole cell lysate.

     

  • Cross-linked ChIP was performed with U-2 OS (human bone osteosarcoma epithelial cell line) chromatin extract and 5 μg of either control rabbit IgG or ab230358. The precipitated DNA was detected by PCR with primer set targeting to CCND2.

  • All lanes : Anti-Tet2 antibody - N-terminal (ab230358) at 1/5000 dilution

    Lane 1 : HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate/extract
    Lane 2 : DDDDK-human Tet2-transfected HEK-293T whole cell lysate

    Lysates/proteins at 30 µg per lane.

    Secondary
    All lanes : HRP-conjugated anti-rabbit IgG

    Predicted band size: 224 kDa



    5% SDS-PAGE gel.

  • Paraffin-embedded human breast cancer tissue stained for Tet2 using ab230358 at 1/500 dilution in immunohistochemical analysis.

  • Paraffin-embedded human cervical carcinoma tissue stained for Tet2 using ab230358 at 1/500 dilution in immunohistochemical analysis.

References

ab230358 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab230358.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up